ENVALITH
リオン株式会社 logo

RION CO., LTD.

6823・Prime Market・Electric Appliances

Official website
リオン株式会社 logo
RION CO., LTD.6823

Business

Rion Co., Ltd., founded in 1944, is a precision measuring instrument manufacturer operating three businesses: the Particle Counter Business (liquid-borne and airborne particle counters), the Medical Equipment Business (Medical Testing Equipment such as hearing aids and audiometers), and the Environmental Instruments Business (acoustic and vibration measuring instruments such as sound level meters, vibration meters, and seismometers). Its principal customers span a wide range of sectors, including semiconductor manufacturing plants, medical institutions such as otorhinolaryngology departments and university hospitals, and infrastructure-related operators. In the domestic market, the company holds a high market share across all of its major products, and in recent years it has been promoting expansion into Europe by leveraging its European subsidiary, Norsonic AS (Overseas Development, Manufacturing, Sales, and Service), as well as expansion into Southeast Asia. The company is listed on the Prime Market of the Tokyo Stock Exchange.

Business Model

The Group operates as a research and development-oriented company, developing and manufacturing products in-house and providing sales and services through domestic sales subsidiaries (Kyushu Rion, East Japan Rion, Tokai Rion, etc.) and Rion Service Center, adopting a vertically integrated model. It employs a build-to-forecast production system and maintains a stable sales base backed by high domestic market share. The operating margin on sales for FY2026 (ending March 2026) reached 15.3%, with the continuous introduction of high value-added products supporting profitability.

Company Strengths

The Annual Securities Report explicitly states that "all of the company's main products have secured high market share in the domestic market," which is the result of pioneering unique businesses not undertaken by other companies. The company's track record of continuously launching advanced products—including the world's first digital hearing aid (1991), the world's first waterproof custom-made hearing aid (2005), and the world's first cartilage conduction hearing aid (2017)—has been the source of its competitive advantage.

In FY2026 (ending March 2026), the company achieved net sales of ¥28,502 million, operating profit of ¥4,362 million (margin of 15.3%), and ROE of 10.1%, achieving ahead of schedule its own targets for FY2031 (ending March 2031) of an operating margin of 15% or higher and ROE of 10% or higher. Cash flow from operating activities was also stable at ¥4,165 million, and the company maintains a solid financial base with net assets of ¥34,803 million and a high equity ratio.

R&D expenses for FY2026 (ending March 2026) reached ¥2,521 million (approximately 8.9% of net sales), with new products continuously developed and launched across the Particle Counter Business (¥630 million), Medical Equipment Business (¥1,025 million), and Environmental Instruments Business (¥865 million). During the fiscal year, the company successively launched the audiometer "AA-H2," the rechargeable in-the-ear type hearing aid "Rionet Plus," the strong motion seismograph "SM-31," and the vibration analyzer option "VX-14D."

ENVALITH's Perspective

For FY2026 (ending March 2026), net sales of ¥28,501 million, operating profit of ¥4,361 million, and profit attributable to owners of parent of ¥3,345 million all reached record highs, which can be viewed favorably. On the other hand, segment profit in the Particle Counter Business declined 14.0% year on year, from ¥2,779 million in the previous period to ¥2,391 million, as increased capital investment to meet strong product demand and higher development costs for cutting-edge models weighed on profitability. The outlook for a recovery in profit margins going forward will be an important point to monitor.

Operating profit in the Environmental Instruments Business improved substantially, rising 348.2% year on year from ¥163 million in the previous period to ¥733 million. This was driven by ongoing efforts to improve operational efficiency, along with continued demand for domestic infrastructure-related capital investment and expansion of overseas sales channels. However, since this partly depends on external factors such as infrastructure investment policy trends and economic fluctuations in overseas markets, it will be necessary to continue verifying whether this improvement is structurally sustainable or the result of temporary demand concentration. Under the medium-term outlook, the plan calls for only a 15% increase in net sales and a 2% increase in operating profit over three years, leaving some room for a cautious view on the sustainability of profit margins.

The company has disclosed a three-year growth plan targeting net sales of ¥32,000 million and operating profit of ¥5,350 million for FY2029 (ending March 2029). In the Particle Counter Business, continued semiconductor investment related to generative AI is assumed as an external factor, which entails exposure to market volatility risk. In the Medical Equipment Business, cautious capital investment stances at university hospitals and other institutions persist, and the timing of a full-fledged recovery in equipment replacement demand will be a key variable in achieving the plan. The company's forecast for FY2027 (ending March 2027) of net sales of ¥29,700 million and operating profit of ¥4,700 million anticipates steady growth from the previous period, and progress toward achieving this will warrant close attention.

Growth Strategy

Continued revenue growth across the three businesses of semiconductors, medical, and environment, aiming for sales of ¥32,000 million and operating profit of ¥5,350 million in FY2029 (ending March 2029)

Capturing expanding demand for liquid-borne particle counters driven by the construction and expansion of semiconductor manufacturing plants for generative AI-related data centers. Leveraging strengthened production capacity to win new orders while addressing demand for state-of-the-art models. Toward FY2029 (ending March 2029), revenue is expected to increase by approximately 19% and operating profit by approximately 32%.

For hearing aids, expanding sales through continued promotion of the new product Rionet Plus and strengthened collaboration with otolaryngology clinics. For medical testing equipment, promoting enhanced sales of new products and reliably winning orders from newly opened clinics in Japan. Toward FY2029 (ending March 2029), revenue is expected to increase by approximately 5% and operating profit by approximately 17%.

In Japan, reliably winning equipment renewal orders for seismometers and aircraft noise monitoring systems while expanding the market through the introduction of new products. Overseas, promoting expansion of sales channels in the European and Asian markets by leveraging Norsonic AS (Overseas Development, Manufacturing, Sales, and Service) and others. Due to strengthened future investment such as new product development, operating profit growth in FY2029 (ending March 2029) is expected to be limited to approximately 2%.

The annual dividend for FY2026 (ending March 2026) is ¥85 (up from ¥70 in the previous fiscal year), with a dividend payout ratio of 31.3% and a dividend-to-net-assets ratio of 3.2%. The forecast dividend for FY2027 (ending March 2027) is ¥90, planning a further increase, with a policy of continuously strengthening shareholder returns in line with business expansion.

Last updated: July 19, 2026